Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Revive Therapeutics has signed a material transfer agreement (the MTA) with a global pharmaceutical company headquartered in Osaka, Japan.
Subscribe to our email newsletter
Pursuant to the MTA, Revive Therapeutics will obtain access to confidential information and clinical trial supply of the drug bucillamine for Revive Therapeutics’ human clinical trial of REV-002, a potential new treatment for gout.
In return, the global pharmaceutical company will have exclusive commercialization rights in Japan, Korea and Taiwan, and Revive will have exclusive commercialization rights in the rest of the world.
Revive Therapeutics CEO Fabio Chianelli noted the company is pleased to have secured this material transfer agreement as it allows us the opportunity to expedite towards a human clinical trial for the treatment of gout.
"This marks an important milestone for Revive as we strive to build relationships with recognized pharmaceutical companies around the globe," Chianelli added.